PATENT PROTECTION FOR CRISPR/Cas-9 TECHNOLOGIES IN BRAZIL

Genome editing using clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated 9 (Cas9) technology holds great potential to accelerate life science research, improve biotechnology, and diagnose and treat human diseases. All over the world, big pharma companies and universities have been investing in said technology and the number of patent applications/patents has been increasing.